GR89,696: A potent κ-opioid agonist with subtype selectivity in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 3, 2001, Pages 1049-1059

  Butelman, Eduardo R ^a   Ko, M C Holden ^b   Traynor, John R ^b   Vivian, Jeffrey A ^b,c   Kreek, Mary Jeanne ^a   Woods, James H ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; BINALTORPHIMINE; ETHYLKETAZOCINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTREXONE; PROLACTIN; RADIOLIGAND; RECEPTOR SUBTYPE; SULFUR 35;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIURESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RHESUS MONKEY; SEDATION;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; BENZENEACETAMIDES; CEREBRAL CORTEX; DISCRIMINATION (PSYCHOLOGY); DIURESIS; ETHYLKETOCYCLAZOCINE; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MACACA MULATTA; MALE; MEMBRANES; MUSCLE RELAXATION; NALTREXONE; PAIN MEASUREMENT; PIPERAZINES; PROLACTIN; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, KAPPA; RESPIRATORY MECHANICS;

EID: 0034883666     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor
2. 2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys
3. Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys
4. Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys
5. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys
6. Kappa-Opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception
7. 2-like receptor agonists
8. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys
9. Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys
10. Enadoline discrimination in squirrel monkeys: Effects of opioid agonists and antagonists
11. Spinal kappa1 and kappa2 opioid binding sites in rats, guinea pigs, monkeys and humans
12. GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus
13. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects
14. Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and beta-funaltrexamine
15. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes
16. Comparison of kappa opioids in rhesus monkeys: Behavioral effects and receptor binding affinities
17. A series of novel, highly potent and selective agonists for the κ-opioid receptor
18. Putative kappa-2 opioid agonists are antihyperalgesic in a rat model of inflammation
19. Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys
20. G-protein-coupled receptor heterodimerization modulates receptor function
21. Ligand binding profiles of U-69, 593-sensitive and-insensitive sites in human cerebral cortex membranes: Evidence of kappa opioid receptors heterogeneity
22. Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects
23. 2 analysis in rhesus monkeys
24. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions
25. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys
26. Dopaminergic neuronal systems in the hypothalamus
27. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine
28. Aquaretic effect of the stable dynorphin-A analog E2078 in the human
29. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors
30. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor
31. Guanine nucleotide-binding protein-coupled and -uncoupled states of opioid receptors and their relevance to the determination of subtypes
32. Mechanism of diuretic action of spiradoline (U-62066E) - A kappa opioid receptor agonist in the human
33. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking
34. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum
35. 3H]bremazocine binding in single and combinatorial opioid receptor knockout mice
36. U50,488 and the kappa receptor. Part II. 1991-1998
37. Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys
38. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells
39. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox
40. Activation of the cloned human kappa opioid receptor by agonists enhances [35S] GTPγS binding to membranes: Determination of potencies and efficacies of ligands
41. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: Evidence for kappa 1 and kappa 2 opioid receptors